Literature DB >> 33328005

[A school-aged boy with nephrotic syndrome with cough for one month and shortness of breath for half a month].

Xiao-Lu Deng1, Chun-Guang Zhao, Xin-Hua Ma, Xia Wang1.   

Abstract

A boy, aged 6 years and 11 months, was admitted due to nephrotic syndrome for 2 years, cough for 1 month, and shortness of breath for 15 days. The boy had a history of treatment with hormone and immunosuppressant. Chest CT after the onset of cough and shortness of breath showed diffuse ground-glass opacities in both lungs. Serum (1, 3)-beta-D glucan was tested positive, and the nucleic acid of cytomegalovirus was detected in respiratory secretions. After the anti-fungal and anti-viral treatment, the child improved temporarily but worsened again within a short period of time. Pneumocystis jirovecii was identified by Gomori's methenamine silver staining in bronchoalveolar lavage fluid. The child was diagnosed with severe pneumonia (Pneumocystis jirovecii and cytomegalovirus infection), acute respiratory distress syndrome, and nephrotic syndrome. After anti-infective therapy with sulfamethoxazole/trimethoprim and ganciclovir and respiratory support, the child still experienced progressive aggravation of dyspnea and tension pneumothorax, and extracorporeal membrane oxygenation (ECMO) was given on day 13 of invasive ventilation. Anti-infective therapy with sulfamethoxazole/trimethoprim, ganciclovir, and linezolid, anticoagulation therapy, sedation therapy, nutrition, and comprehensive management of the respiratory tract were given during ECMO. The child was successfully weaned from ECMO after 72 days, resulting in a length of hospital stay of 134 days. The child was followed up for 6 months after discharge, and there was a significant improvement on lung CT, without organ dysfunction. It is concluded that Pneumocystis jirovecii pneumonia is a potential lifethreatening infection for children with low immunity, and that ECMO can effectively improve the prognosis of children with severe respiratory distress syndrome.

Entities:  

Mesh:

Year:  2020        PMID: 33328005      PMCID: PMC7735935     

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  7 in total

Review 1.  Cytomegalovirus pneumonia.

Authors:  N Salomon; D C Perlman
Journal:  Semin Respir Infect       Date:  1999-12

2.  Recovery from Total Acute Lung Failure After 20 Months of Extracorporeal Life Support.

Authors:  Kristen Nelson-McMillan; Luca A Vricella; Fray Dylan Stewart; John Young; Ashish S Shah; Narutoshi Hibino; John D Coulson
Journal:  ASAIO J       Date:  2020-01       Impact factor: 2.872

3.  Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features.

Authors:  Emir Festic; Ognjen Gajic; Andrew H Limper; Timothy R Aksamit
Journal:  Chest       Date:  2005-08       Impact factor: 9.410

4.  2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.

Authors:  Lorry G Rubin; Myron J Levin; Per Ljungman; E Graham Davies; Robin Avery; Marcie Tomblyn; Athos Bousvaros; Shireesha Dhanireddy; Lillian Sung; Harry Keyserling; Insoo Kang
Journal:  Clin Infect Dis       Date:  2014-02       Impact factor: 9.079

Review 5.  Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia.

Authors:  Helmut J F Salzer; Guido Schäfer; Martin Hoenigl; Gunar Günther; Christian Hoffmann; Barbara Kalsdorf; Alexandre Alanio; Christoph Lange
Journal:  Respiration       Date:  2018-04-10       Impact factor: 3.580

6.  The association between Cytomegalovirus co-infection with Pneumocystis pneumonia and mortality in immunocompromised non-HIV patients.

Authors:  Pervin Korkmaz Ekren; Zehra Nur Töreyin; Payam Nahid; Mert Doskaya; Ayse Caner; Nevin Turgay; Aysin Zeytinoglu; Seray Toz; Feza Bacakoglu; Yuksel Guruz; Selda Erensoy
Journal:  Clin Respir J       Date:  2018-11       Impact factor: 2.570

7.  Paediatric acute respiratory distress syndrome incidence and epidemiology (PARDIE): an international, observational study.

Authors:  Robinder G Khemani; Lincoln Smith; Yolanda M Lopez-Fernandez; Jeni Kwok; Rica Morzov; Margaret J Klein; Nadir Yehya; Douglas Willson; Martin C J Kneyber; Jon Lillie; Analia Fernandez; Christopher J L Newth; Philippe Jouvet; Neal J Thomas
Journal:  Lancet Respir Med       Date:  2018-10-22       Impact factor: 30.700

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.